PeptiSense

@alphavestcap Wasn’t this a seven‑year process, and now it comes down to a matter of days? $10m is still a lot of money before turning on the revenue stream

$nwbo @alphavestcap Baxers Re: SemperFITrader post# 824944 Friday, May 08, 2026 5:10:54 AM SemperFi. At this point I honestly dont know tbh. We once again find ourselves stretching beyond any equivalent precedent and beyond the supposed statutory clock limit for this part of the assessment, but then if the rest of this assessment is anything to go by, this is nothing new for us. A few things I am trying to keep in perspective to stay sane: - If we are to believe what GZ mentioned to someone here, then we are genuinely at the label negotiation phase and CMC must have been approved by the November CHM. I therefore doubt that we are awaiting a further CHM meeting at this point. - For this 2nd CHM > Announcement to go longer than Kisunla and Leqembi (180 and 182 days respectively) that I have previously received highly complicated restricted population approvals, could of course be possible, but I think there would need to be some specific reason in particular. If we have no approval by 29th May then we would be exceeding every single other application of any time and any state of approval for the same approval pathway... - For a potential specific reason, I was recently told by someone (who had this confirmed directly from the MHRA) contrary to what my own research had led me to believe that Variation applications ARE in fact allowed while an assessment is still in process. This is now purely conjecture, but with this given, it opens up the possibility that either FW could have been added to the assessment or (probably slightly more likely) RWD/ Specials/ Phase 1/2 data has been added to the assessment to try and get a conditional approval for DCVax as a monotherapy/ DCVax + Poly ICLC/ DCVax for Grade 3 Gliomas. I'm not giving any weight to these ideas, but it is more a hope that this is the cause for this phase taking so damn long. - I do not think that the company are dragging their feet in order to avoid having to make the 10mil payment to Cognate. At this juncture, the only means they would have to do that would be to slow-walk MHRA requests on purpose to stall the final announcement. Given how much is pivotal on the MA, I therefore find avoiding this 10mil payment hard to believe. GLTA

@kshaughnessy2 @groovygrahams @PK_Fund $NWBO, if the “trades” are fake, why I am still able to buy at $0.20?

Of course, thanks. Any questions just ask. The company has the naked short data. That’s why they sued and why Wall Street is fighting to keep the data secret Naked shorts are rumored in the billions here. The shorts never intended to cover and they can’t afford to cover. The $NWBO “trades” at $0.20 are fake. No one is selling a $.20 stock for a company with a promising glioblastoma treatment. Let’s say there are • 25M naked shorts = shorts lose $250,000 every penny up • 100M naked shorts = $1M loss per penny • 500M naked shorts = $5M loss per penny •If it’s billions - do the math. Naked shorts have to keep the price suppressed to avoid margin calls and forced buy-ins. @Hamnakedshorts

$NWBO stupid question. The shorts have the same info as we have. Anticipating approval, would'nt you think they would have started covering awhile ago?

@ElonMuskAOC @grok Which country of these leaders is most democratic?

Hey @grok remove the most corrupt leader

@MDendream @hoffmann6383 @Cleves_trades Thanks for your thoughts, I am myself disappointed not to see a better explanation why the extreme large addition of authorized shares are needed. After so many years and so close to approval, I think it is fair to present a roadmap to profitability. For now I will vote against.

@hoffmann6383 @Cleves_trades I appreciate that you keep distance. I think that’s important for objectivity $NWBO

$NWBO's Definitive Proxy Statement #tOTMA" target="_blank" rel="nofollow noopener">sec.gov/ix?doc=/Archiv… Annual Shareholder Meeting: Monday, December 29, 2025 at 2pm EST. Audio only link to be provided at a later time. Hope everyone (in the USA) had a good Thanksgiving. I'm finally getting around to reading $NWBO's proxy filed last Friday. Some quick/preliminary thoughts on the votes can be seen below. 1⃣To elect one member to our Board of Directors to serve as Class II Director for a term of three years; ​ I am tentatively voting "Withhold" on Pat Sarma's appointment. Mr. Sarma has no relevant business experience since about 2001, and even prior to said date the business experience doesn't appear relevant to $NWBO's field of business. From public court filings around 2010 it appears Mr. Sarma only dabbles in real estate. Mr. Sarma was part of $NWBO's compensation committee that contributed to the recent derivative lawsuit settlement. Mr. Sarma was on camera sleeping through the last ASM. We need accountability and relevant experience instead of a 'yes man' on the board. That's why I'm voting "Withhold" on Pat Sarma's appointment. 2⃣To ratify the appointment of Cherry Bekaert LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025; I'm voting "For" the appointment of our accounting firm. ​ 3⃣To approve an amendment to our Amended and Restated Certificate of Incorporation, as amended (the “Certificate of Incorporation”), to increase our authorized shares of common stock from 1,700,000,000 to 2,600,000,000, par value $0.001 per share (the “Common Stock”); I'm voting "For" the increase in authorized shares. We're a public company that doesn't have any revenue (minus a bit from Advent) so dilution is an unfortunate reality. ​ 4⃣To approve, on an advisory basis, the Company’s executive compensation; and I'm tentatively voting "Abstain" on the advisory vote for executive compensation. I want to see management bonuses and awards attached to timelines moving forward. That way, if timelines aren't met and dilution continues the management feels a bit of the same pinch retail does. From the derivative lawsuit, the awards appear setup in such a manner where the directors and executives don't feel the same pinch from dilution that the retail investor feels. Comparing ourselves to Novocure, the details surrounding how awards and bonuses are given at Novocure makes $NWBO's compensation sections look extremely barren of detail. ​ 5⃣To act upon such other matters as may properly come before the meeting or any adjournments or postponements thereof. Nothing to vote on with #5. Further Thoughts Above all else, I hope $NWBO starts to act like a public company. One that does quarterly conference calls. One that attempts to attract new investors with a slide deck. A company that attracts new investors through transparency into their plans, instead of having to parse 10 K/Qs for sparse details and then speculating on said sparse details. A company that attaches executive and director awards and bonuses to pre defined goals and timelines. If we are going to have to dilute, then at least behave in the way a customary public company would behave and try to attract new investors to offset some of the impact of further dilution. Even one of the consultants $NWBO hired referred to $NWBO as "more akin to a privately-held company". See Image 1. It's time we start acting in such a way to attract further investments and align awards and bonuses with transparent goals and timelines. $NWBO is on the verge of a regulatory approval for a groundbreaking cancer vaccine. It's amazing $NWBO has made it this far, but now it is time to buckle up and start acting in such a manner to attract further investments! This is my own preliminary thoughts as to the above linked Proxy. Everyone needs to do their own research and vote their own way. Respect differing opinions.

@ATLnsider It does say “over the cost of current care”, it will be well above 15k per dose. $NWBO

UK has raised QALY cost threshold by 25% for new drugs. New range is $25,000 to $35,000. This bodes well for $NWBO #DCVax-L favorable NICE appraisal. At a per dose cost of $15K to $20K, a positive QALY appraisal should be coming. Here are my thoughts: investorshub.advfn.com/boards/read_ms…

@alphavestcap November 27/28

$nwbo @alphavestcap #chm-meeting-dates" target="_blank" rel="nofollow noopener">gov.uk/government/org… December meeting:12/18-19.

@DCVaxDefender Any idea about how many patients per month Sawston is handling now?$NWBO could be quickly approaching break-even.

@hoffmann6383 @jascanlan @FlemmingBruce Doesn’t make sense to me to do this deal before confirmation of approval. Why take any chance at all. Any benefit reasons? Tax?

@jascanlan @FlemmingBruce If I were LP I wouldn't have done this deal unless I had confidence in approval. Otherwise, I just threw away Advent for nothing.

@hoffmann6383 and @FlemmingBruce I finally got a chance to read the full PR. That’s some pretty punchy language about scale up. Does that change your view on NWBO’s likelihood of MAA? *not investment advice but… would you write that down if rejection was still possible?*

@elonmusk If you start fresh, could you fill the house, the senate, the Sec, the FDA, etc which people that are not managed by Wallstreet, HF managers, Big Pharma. Is that not the real problem? Maybe it is more difficult than putting some guys or girls on Mars!

The America Party is needed to fight the Republican/Democrat Uniparty

@ajw02360 @andrewcaravello They do not use surnames anymore at the government?

@andrewcaravello But $NWBO is currently under a RFI. You keep saying they are changing all the rules just for DCVax but the email I just received 7 hours ago suggests NW is under a RFI and haven’t answered, or the application has been rejected (least likely IMO) and NW has not announcemed it yet

$NWBO 🧭 Blueprint vs. Biology: Why DCVax Represents the Future Platform for Immune-Based Cancer Treatment 🎯 Strategic Thesis This is the crux of modern medicine’s problem, and the reason DCVax represents a true paradigm shift. Today, cancer drug development is built on a cycle of synthetic hope: molecules are engineered through combinatorial chemistry, optimized, and tested, then deployed in the hope they’ll still match a moving target. It’s reactive by design. DCVax flips the script. It doesn’t rely on betting that a synthetic molecule will still matter when resistance emerges. It trains the immune system itself to adapt in real time, using the tumor’s full fingerprint as its input. This isn’t a better version of the old model. This is the model that finally matches the biology. The old model is like designing a single key in a lab, hoping it still opens a lock that’s constantly changing shape. DCVax is different. It’s like handing the immune system a master locksmith’s kit and training it to adapt in real time, no matter how many times the tumor changes the lock. At the heart of modern oncology is a mismatch: drug discovery has evolved through combinatorial chemistry, but cancer biology evolves faster. The modular trials that now define precision oncology, like AstraZeneca’s ORCHARD, are built to deploy targeted therapies designed through synthetic optimization. But these trials are only as strong as the assumptions they rely on. The blueprint was engineered in the lab. The tumor rewrites it in real time. DCVax offers an alternative: a system built not to match a single mutation, but to learn and respond to the tumor’s entire antigenic fingerprint. It is not the next iteration of the blueprint, it’s the immune system made programmable. 🧬 I. The Precision Illusion AstraZeneca’s ORCHARD trial was a modular Phase 2 platform, designed to deploy targeted therapies based on resistance patterns in EGFR-mutant NSCLC. Each drug in its arsenal, from osimertinib to savolitinib to datopotamab deruxtecan, was the product of sophisticated combinatorial chemistry: libraries of small molecules and antibodies screened, optimized, and matched to a mutation. But in the real world, the biology moved faster. The necitumumab arm, designed to block EGFR externally while osimertinib blocked it internally, failed to deliver meaningful benefit. ORR was 11%. Median PFS was 4.0 months. The target had already changed. The tumor had already slipped past. What this shows is that no matter how elegant the chemistry, if the biology escapes it, the outcome falters. 🧠 II. Cancer Evolves, But Immunity Can Learn Tumors don’t just mutate, they adapt. They switch lineages, exploit metabolic escape, evolve in immune-privileged microenvironments. AstraZeneca’s 2023 review outlines how the tumor microenvironment (TME) subverts immune responses through lipid peroxidation, ferroptosis, and peroxynitrite-mediated distortion of antigen presentation. DCVax bypasses that entire system. By loading a patient’s tumor lysate into dendritic cells outside the body, it trains immune memory in a clean space. It does not rely on selecting targets. It doesn’t require the trial-and-error of combinatorial screening. Combinatorial chemistry involves synthesizing and testing vast libraries of structurally diverse molecules, typically small molecules or antibody fragments, to find those that bind to a desired biological target. It’s the brute-force, high-throughput foundation of much of modern drug discovery. From kinase inhibitors to monoclonal antibodies, nearly every precision therapeutic on the market began as one compound among millions in a synthetic library. It’s an elegant process, but it assumes the problem stays put. It presumes that if you can find the right molecular match in the lab, the biology in the patient will still care. It’s fundamentally retrospective: match the molecule to yesterday’s mutation, and hope the target holds tomorrow. And sometimes it does, just often enough to keep the cycle alive. Eventually a squirrel catches a nut. But in rapidly evolving systems like cancer, hope isn’t a strategy. It’s a delay. DCVax doesn’t wait. It doesn’t rely on guesswork. It builds immunity by training on the tumor’s full reality, not just its last known mutation. This approach has driven much of modern precision drug development. DCVax doesn’t require it. Instead, it turns the body’s immune system into a combinatorial engine of its own. Dendritic cells expose T cells and B cells to the tumor’s full antigenic range. The immune system decides what to target, and how to evolve with it. 🚀 III. MORPHEUS, KEYMAKER, ORCHARD: Platforms That Pivot MORPHEUS (Roche), KEYMAKER (Merck), and ORCHARD (AstraZeneca) represent the best efforts of adaptive trial logic. They are modular, smart, and responsive. But they all still chase biology from behind. Each depends on drug constructs that were built through synthetic logic. Each assumes resistance will express in a detectable, actionable way. DCVax assumes the opposite: that resistance is unpredictable, that evolution is messy, and that the only sustainable strategy is immunologic memory that’s trained on everything the tumor is and might become. 🌐 IV. Advent and the Cambridge Immuno-Stack DCVax is manufactured at Advent BioServices, a fully licensed ATMP facility located in Sawston, UK, just 7 miles from AstraZeneca’s Discovery Centre in Cambridge. This proximity isn’t just logistical, it’s strategic. It reflects how manufacturing infrastructure, scientific innovation, and regulatory flexibility are quietly converging in one of the most advanced biomedical corridors in Europe. On one end of the corridor, AstraZeneca leads global research in immuno-oncology, resistance mapping, and tumor microenvironment remodeling. On the other, Advent operationalizes decentralized, GMP-compliant manufacturing of personalized cell-based therapies like DCVax. While there is no formal partnership between Advent and AstraZeneca, their co-location within the Cambridge–Sawston corridor creates a unique and functional alignment. Both are regulated by the MHRA, and both are advancing cell- and immune-based platforms under UK-specific frameworks. In particular, Advent is licensed under SI 87, which allows it to manufacture and export personalized medicines, including under the “Specials” provision, without needing centralized marketing authorization, as long as physician oversight is documented. This corridor functions as a live model of scalable, decentralized immunotherapy deployment. Shared scientific talent, overlapping vendors, and parallel infrastructure (cold chain, QC testing, regulatory consultants) enable efficient translation from insight to action. AstraZeneca maps the biology; Advent produces the response. DCVax brings it all together, delivering patient-specific immune education through a system built within the very infrastructure that modern pharma is now beginning to depend on. The Cambridge–Sawston corridor isn’t just where science happens. It’s where immunotherapy becomes operational at scale. DCVax is manufactured by Advent BioServices in Sawston, UK, just outside Cambridge, where AstraZeneca’s Discovery Centre leads global trial design. The geography is more than symbolic. Under the UK’s MHRA and SI 87 framework, Advent is licensed to manufacture and deploy cell-based immunotherapies globally. Tissue in, vaccine out. The Cambridge–Sawston corridor isn’t just a cluster. It’s a preview of decentralized immune infrastructure. 🧠 V. Dmitry Gabrilovich: Architect of the Tumor–Immune Interface Dr. Dmitry Gabrilovich’s work has defined how tumors exploit the immune system, and strategically, he sits within the same Cambridge–Sawston corridor where this new infrastructure is taking shape. As Chief Scientist of Cancer Immunology at AstraZeneca’s Discovery Centre in Cambridge, Gabrilovich not only helps lead the research agenda but occupies the physical and institutional space where science meets deployment. As Chief Scientist of Cancer Immunology at AstraZeneca, he guides strategic direction in tumor immune evasion research and translational immunotherapy design. His findings show that myeloid cells become immunosuppressive under TME influence, driven by oxidized lipids, ferroptosis, and peroxynitrite. Dendritic cells are silenced. Antigen presentation collapses. T cells are blinded. These aren’t rare cases, they’re the rule. His 2023 report with AstraZeneca reframes the TME as a proactive barrier to immunotherapy. It explains why so many checkpoint strategies plateau, why T cells don’t engage, and why resistance keeps returning. DCVax was built for this exact biology. By creating immune memory outside the suppressive system, it delivers antigen clarity before distortion occurs. It bypasses the battlefield, and trains the army beforehand. Gabrilovich reveals the trap. DCVax was designed to avoid it. And he’s taken notice. When the DCVax Phase III trial was published in JAMA Oncology, Gabrilovich publicly noted the significance of the results, stating: “The results appear promising and support the idea that dendritic cell-based vaccines could be a viable path forward, particularly if they’re able to overcome immunosuppression seen in the tumor microenvironment.” This isn’t an endorsement, but it is something more rare: a signal from one of the field’s most respected skeptics that something in the design of DCVax may have gotten it right. The man who mapped the immunologic trap has acknowledged a path out. And it runs through ex vivo trained immunity. Dr. Dmitry Gabrilovich’s work describes how the TME deactivates immunity: through lipid oxidation, ferroptosis, and immune editing. His 2023 AstraZeneca co-authored paper reframes the TME as an intelligent adversary. DCVax was designed for that adversary. It teaches the immune system to act before the sabotage sets in. 🎯 VI. The Strategic Convergence All the components of modern oncology, science, infrastructure, and clinical design, are pointing toward the same conclusion: •AstraZeneca has mapped the ways tumors shut down the immune system through oxidative stress, myeloid dysfunction, and antigen distortion. •ORCHARD has demonstrated that even the most advanced precision trials struggle when resistance evolves faster than drugs can be matched. •MORPHEUS (Roche) and KEYMAKER (Merck) are adapting trial platforms to be faster, more modular, more reactive—but they still rely on hitting the right target at the right moment. •Advent BioServices, under the UK’s MHRA and SI 87, is now capable of manufacturing and delivering cell-based therapies at scale, directly from tissue to vaccine. Each of these pieces addresses one part of the challenge: understanding resistance, keeping pace with it, or delivering treatment faster. But only DCVax brings all of it together. DCVax absorbs the complexity of the tumor microenvironment, bypasses the limitations of static targeting, leverages a fully scalable infrastructure, and trains a patient’s own immune system to anticipate (not chase) disease. That’s the convergence: biology, trial design, and manufacturing are aligning behind an idea whose time has come. Not a better blueprint. A living map. Because the immune system isn’t just part of the plan. It is the platform. 🔟 X. Final Thought: A New Lens for Oncology DCVax is more than a therapy. It’s a lens through which to reimagine what cancer treatment actually demands. It challenges the assumption that medicine must always begin with a molecule. That we must guess the next target and hope the biology cooperates. That we must use chemistry to fight a system that evolves faster than our designs. Instead, it argues for a new foundation: one that assumes evolution, that welcomes antigenic complexity, and that uses the body’s own machinery to generate durable, evolving solutions. This is not the end of drug development. It’s the shift from drug-first thinking to system-first design, where immunity is the infrastructure, and personalization is the default. In that sense, DCVax is not just a turning point. It’s a reframing of the entire battlefield. 👥 Patient Perspective: A Platform That Meets You Where You Are For the patient, DCVax doesn’t just represent a scientific pivot, it’s a lifeline not constrained by drug eligibility, mutation status, or the limitations of trial timing. It turns tumor tissue into therapy, not in theory, but in practice. It’s a platform built for adaptation, not restriction, designed to train the immune system around your disease, not force your disease into someone else’s drug template. This is what precision was always supposed to mean. 🔭 Looking Forward: The Next Chapter What we see in DCVax today may be only the beginning. As regulators embrace distributed manufacturing and real-world adaptive platforms, this approach could unlock the era of combinatorial immune programming, not by adding more drugs, but by deepening the immune system’s training. From tissue-agnostic oncology to combination vaccine stacks, the path ahead no longer depends on the next molecule. It depends on the next immune instruction set. $AZN $MRK $BMY $RHHBY $CRSP $SGEN $MRNA $PGEN $IMMP $TSVT

@Dynafxd2010 It is simply not true

I’ve been thinking about tariffs lately and could use some insight. Why do people say tariffs hurt America, but other countries that use them don’t seem to face the same criticism? If they’re bad for one economy, shouldn’t they be bad for all? I’m honestly curious. And if Trump’s tariff plans are such a terrible idea, why are other countries quick to tell the media they’ll raise their own tariffs in response? If tariffs are an economic mess, wouldn’t the smart move be for everyone to just drop them instead

@smith348572 @xMarketNews @UCLANsgy How is this possible if they just keep shorting without covering. It seems all of the institutional investors stay away because of these hedge funds, not because they do not believe in DC-vax, just because of manipulation. Please explain why I am wrong.

$NWBO has the potential to generate the MOASS with +3B naked shorts versus 1,3B shares outstanding. The treatment developed by Dr. Liau @UCLANsgy is a game-changer for cancer patients, delivering the best outcomes in 17 years for newly diagnosed GBM (glioblastoma) and the most significant results in 27 years for recurrent GBM—all with no side effects. Aside from the lawsuit, the company has applied for commercial production in the UK, with approval anticipated at any moment.

JUST IN🚨 Ken Griffins Citadel May be Getting Exposed for Market Manipulation - This comes after the Cancer company $NWBO accused Citadel of market manipulation by spoofing, impacting their stock prices from 2017 to 2022 THE CASE IS ABOUT TO GO INTO DISCOVERY!!

@hoffmann6383 Hoff, can conclusion 3, “the SAC sufficiently pleads the elements of a manipulative act, scienter, and reliance.”, be used by Laura that the spoofing is ongoing?

🚨BREAKING: $NWBO's spoofing lawsuit likely moves to discovery as magistrate recommends the motion to dismiss be GRANTED IN PART and DENIED IN PART. Magistrate Judge Stein recommended The Motion to Dismiss ("MTD") in the $NWBO spoofing case be DENIED IN PART and GRANTED IN PART.* "In sum, the Court concludes that: (1) the SAC sufficiently pleads loss causation with respect to the approximately 40 million shares of stock sold by NWBO at prices derived from closing prices on dates when Spoofing Episodes occurred; (2) the SAC fails to sufficiently plead a long-term, persistent negative impact on NWBO’s stock price, requiring dismissal of Plaintiff’s claims relating to the approximately 234 million other shares of stock sold during the Relevant Period; and (3) the SAC sufficiently pleads the elements of a manipulative act, scienter, and reliance." See Image 1. This means the case is likely to move on to the discovery phase as to the 40 million shares of stock $NWBO sold at depressed prices. This case holds enormous implications for the wider market which will be discussed in more detail below. The Defendant market makers are some of the biggest MMs in the world, including @VirtuFinancial and @citsecurities, among others. ➡️The Case Northwest Biotherapeutics, Inc v. Canaccord Genuity LLC, 1:22-cv-10185, (S.D.N.Y.) [1] First, I'll give a 50,000 foot view of the Case. Next, I'll identify the parties and give some thoughts on what this ruling could mean to those involved in the case and to the wider market. Lastly, in a follow up post, I'll review Magistrate Stein's Report and Recommendation in detail. ➡️The 50,000 foot view This is a case where $NWBO has alleged harm due to illegal share price manipulation by some of the biggest market makers in the world and their (likely) hedge fund clients so that they could make a dollar at the expense of real life cancer patients without any other treatment options. There has been no approved treatments for newly diagnosed glioblastoma for over two decades and these long suffering cancer patients are having to wait (with time they don't have) even longer for $NWBO's DCVax-L because of illegal market manipulation delaying its' access to the public. Glioblastoma is one of the most deadly forms of cancer. There are 12,000+ glioblastoma diagnoses per year in the United States according to the American Brain Tumor Association. [2] The recurrence rate is nearly 100%. [3] The peer-reviewed DCVax-L JAMA publication showed 25 of 232 newly diagnosed glioblastoma patients alive at five years who took $NWBO's DCVax-L whereas the external control population that didn't take DCvax-L showed zero patients alive at five years out of 1,366 patients. [3] See Image 2. Similar positive long term survival was seen with DCVax-L in recurrent glioblastoma patients. See Image 3. This means that for every year longer it takes for $NWBO's DCVax-L to hit the market 1,293 newly diagnosed glioblastoma patients in the United States will die an unnecessary death. Add in the UK, EU, Japan, and the RoW and that number is much much higher. That's the real life impact on cancer patients throughout the world and it doesn't even take into account the financial terror on the market, specifically $NWBO and its' investors. You can read more about the impact of spoofing on $NWBO's share price here: x.com/hoffmann6383/s… ➡️What did @JoeMillerJr and the Financial Times think of $NWBO's spoofing case? "...huge if true" [4] ➡️Are $NWBO's allegation's true? Magistrate Stein is stating $NWBO's claim is plausible on its' face as to 40 million shares of stock and there is a reasonable inference that defendant is liable for the alleged misconduct. A jury will likely make the final determination as to the merits of the claims. “To survive a motion to dismiss, a complaint must contain sufficient factual matter, accepted as true, to ‘state a claim that is plausible on its face.’” Ashcroft v. Iqbal, 556 U.S. 662, 678 (2009) (quoting Bell Atlantic Corp. v. Twombly, 550 U.S. 554, 570 (2007)). A claim is plausible “when the plaintiff pleads factual content that allows the court to draw the reasonable inference that the defendant is liable for the misconduct alleged.” Iqbal, 566 U.S. at 678. [5] ➡️Plaintiff Northwest Biotherapeutics, Inc. ("NWBO") "NWBO is a clinical stage biotechnology company focused on the development of personalized cancer vaccines designed to treat a broad range of solid tumor cancers more effectively than current treatments, and without the side effects of chemotherapy, through a proprietary manufacturing technology which enables the Company to produce a personalized vaccine in an efficient and cost-effective manner." [6] $NWBO has submitted their Marketing Authorization Application for approval of DCVax-L in the UK for BOTH newly diagnosed and recurrent glioblastoma and are awaiting an approval decision: nwbio.com/northwest-biot… ➡️Defendants Canaccord Genuity LLC @CG_Driven, Citadel Securities LLC @citsecurities, G1 Execution Services LLC, GTS Securities LLC, Instinet LLC, Lime Trading Corp. @LimeTrading_, and Virtu Americas LLC @VirtuFinancial ➡️Case Summary "Northwest Biotherapeutics (NWBO) claims that the market makers deliberately engaged in repeated manipulative spoofing of its stock from December 5, 2017 – August 1, 2022... During the Relevant Period, Defendants engaged in spoofing to manipulate the price of NWBO shares on OTC Link LLC and NYSE ARCA Global OTC, thus creating an imbalance in the market for NWBO shares and inducing other market participants to buy or sell at artificial prices. In order to carry out their spoofing scheme, Defendants placed tens of millions of Baiting Orders and executed millions of orders at manipulated prices during the Relevant Period. Indeed, Defendants engaged in spoofing on 395 of 1,171—or nearly 34%—of the trading days during the Relevant Period. Plaintiff NWBO sold over 274 million shares at manipulated prices as a result of Defendants’ actions, over 40 million shares of which were sold at the closing price on dates where Spoofing Episodes occurred. By repeatedly and brazenly manipulating the market through their spoofing, Defendants directly impacted the price of NWBO’s shares in the market, causing Plaintiff significant losses as it sold millions of shares of NWBO stock at artificially depressed prices." [7] ➡️Why are Defendant Market Makers and their hedge fund clients spoofing $NWBO Stock? One reason put forth by $NWBO and their lead attorney, Laura Posner, is for the purpose of a naked short covering scheme: "And like here, the plaintiff alleged that defendants sought to benefit from their spoofing by obtaining shares at below-market prices in order to cover short positions established through a related alleged scheme of naked short selling." (Emphasis added) [8] ➡️Do we know the potential number of $NWBO naked short shares? No. ➡️Who is $NWBO's lead attorney, Laura Posner? "Her cases include 6 of the top 100 securities fraud class action settlements of all time, including In re Wells Fargo, the 17th largest securities fraud recovery for investors ever." "Prior to joining the firm, Laura was appointed by the New Jersey Attorney General to serve as the Bureau Chief for the New Jersey Bureau of Securities – the top securities regulator in New Jersey. In that capacity, she was responsible for administrating and enforcing the New Jersey Uniform Securities Law and regulations thereunder, as well as managing and overseeing the employees who staff the Bureau of Securities." For more information about Laura Posner see: cohenmilstein.com/bio/laura-h-po… ➡️What does the recommendation to deny the MTD likely mean?⭐️ ✅Judge Woods is very likely to adopt Magistrate Judge Stein's recommendation to deny the MTD ✅A denial of the MTD means the case moves on to discovery. ✅ Parties, including Hedge Funds, involved in spoofing will be identified. See: x.com/hoffmann6383/s… ✅The hedge funds involved in said illegal behavior will be served subpoenas and any feeble attempts to dodge process servers will be dealt with by the courts: x.com/hoffmann6383/s… ✅Hedge funds and market makers may obfuscate but they will ultimately have to turn over relevant trading records: x.com/hoffmann6383/s… ✅Hedge funds, market makers and their agents manipulating $NWBO's share price, or colluding with those that do so, have been put on notice that their behavior is now under a microscope and subject to third party subpoenas: x.com/hoffmann6383/s… @John_Hempton @MidwestHedgie @muddywatersre @AndrewTobias @adamfeuerstein ✅Spoofing experts have developed sophisticated algorithms to detect spoofing: x.com/hoffmann6383/s… ✅Experts could discover much more spoofing incidents than what $NWBO listed in their Complaint once $NWBO obtains the trading data of Defendants and their hedge fund clients. Here is an example of another spoofing case where the expert discovered about 10x more spoofing incidents than what was initially listed in the complaint: x.com/hoffmann6383/s… ✅While this is a civil case, spoofing is also a crime. Illegal behavior may be referred to the DoJ. People go to jail and pay large monetary fines for spoofing (in addition to any civil penalties): justice.gov/opa/pr/former-… ✅Plaintiffs will get to look under the hood of the various market makers including what programs they use to monitor illegal trading, i.e. Actimize at @MerrillLynch: x.com/hoffmann6383/s… ✅The Market Makers' Scapegoat, Adam Feuerstein and @statnews, could be subpoenaed. For more information on how Market Makers use Mr. Feuerstein as cover in legal filings for illegal trading see: x.com/hoffmann6383/s… ✅@adamfeuerstein and his employer @statnews, which is owned by the @BostonGlobe, could be looking at a deposition where they would have to answer questions as to Mr. Feuerstein's actions: x.com/hoffmann6383/s… x.com/hoffmann6383/s… ✅The Defendant Market Makers face significant liability in this spoofing case, including punitive damages. See: x.com/hoffmann6383/s… ✅Fear of punitive damages is one of many reasons a market maker might settle. In fact, I believe we saw our first spoofing lawsuit settlement here: x.com/hoffmann6383/s… ✅Copycat cases are likely to follow as Defendant's claim that this type of trading is "bedrock market-making activity" that is done in "virtually every stock in every trading venue across the country..." (emphasis added) "This is bedrock market-making activity that the Securities and Exchange Commission has explained is an “indispensable part of an efficient and liquid market.”3 Yet NWBO’s contrived theory would convert routine, regulated market making in virtually every stock in every trading venue across the country into securities fraud, flooding the courts with frivolous copycat lawsuits attempting to end-run the PSLRA, potentially upending the entire U.S. equity market system." [8] On the other hand, the Southern District of New York found Defendant Market Makers identified the Market Maker's trading to bear "all these indica of spoofing." "The FAC contains particularized factual allegations evincing all these indicia of spoofing." [9] ✅Doug Cifu (@Dougielarge, CEO of $VIRT) and @VirtuFinancial petitioned the SEC in July '24 to make it easier to delist companies under $1 under the guise they are looking out for the best interest of retail shareholders [10] while at the same time engaging in alleged rampant share price manipulation that is harmful to these same retail shareholders and executing 50%+ of trades in dark pools with zero transparency [11]. The same Doug Cifu that stated this lawsuit will be dismissed and end with Rule 11 sanctions against $NWBO. See Image 4. Mr. Cifu has always been, and will remain, grifter extraordinaire: x.com/hoffmann6383/s… *Note, the partial denial of the MTD is not final until Judge Woods' ruling, but he is very likely to follow Magistrate Stein's recommendation to deny the MTD. Judge Woods adopted in full the first Report & Recommendation by Magistrate Stein on the initial MTD. [1]courtlistener.com/docket/6657959… [2]abta.org/tumor_types/gl…. [3]jamanetwork.com/journals/jamao… [4]ft.com/content/4fe0f0… [5]storage.courtlistener.com/recap/gov.usco… [6]cohenmilstein.com/case-study/nor… [7]Docket #115, courtlistener.com/docket/6657959…… [8]storage.courtlistener.com/recap/gov.usco… [9]storage.courtlistener.com/recap/gov.usco… [10]x.com/hoffmann6383/s… [11]bloomberg.com/news/articles/… @SECGov @DevinNunes @realDonaldTrump @elonmusk $MMTLP $GME $AMC @JoeMillerJr @Justinbaer @KatrynaJill @pulte @PamBondi @Kash_Patel @TheJusticeDept

@hoffmann6383 @UBS Great news. Do you know how long it took before the MTD was issued? Comparable?

🔊Breaking News: Federal Court Allows Second Spoofing Case against Market Maker to Proceed The Case: Phunware Inc. v. UBS Securities, LLC, 1:23-cv-06426 (SDNY) Plaintiff: $PHUN Defendant: @UBS Market makers are now zero for two in trying to get spoofing lawsuits (an illegal form of market manipulation) tossed at the motion to dismiss stage. Why is this important? It sets precedent for the potentially largest ongoing spoofing case where $NWBO is trying to survive a Motion to Dismiss (MTD) against the largest market makers in the world, including @VirtuFinancial and @citsecurities, among others. These lawsuits, and especially the $NWBO spoofing lawsuit, have the potential to significantly alter the financial landscape. I'll go into more detail on this point once the $NWBO MTD Report and Recommendation is issued. How is $PHUN similar to the $NWBO spoofing case? ✅Same lead attorney - Laura Posner ✅Nearly identical complaints ($NWBO Image 1, $PHUN Image 2) ✅Both in Southern District of New York ✅Same issue before the court - loss causation What did the Court in PHUN state? See Image 3. Plaintiff sufficiently plead loss causation to survive a MTD under the temporal proximity theory. The Court is not addressing the long-term price impact because it is unnecessary at this stage. Plaintiff plead loss causation with enough specificity to satisfy the heightened standard under Rule 9(b) Thoughts This isn't binding precedent for the $NWBO spoofing lawsuit, but it is certainly persuasive. Nearly identical cases. Exactly on point. Same attorney. Don't be surprised if we see Posner update the Court in $NWBO's spoofing case of this ruling. Keep an eye out for the $NWBO Report and Recommendation on the pending MTD. It should be coming any day now. Market makers and their hedge fund clients are one step closer to accountability. Happy Thanksgiving!

@noor12141979 @elonmuskADO 13.162

@elonmuskADO Each single earpod= 5 so for 2 (10) Each person =5 Each watch =2 So the Arithmetic proces is clearly simple, but the last step ( the multiplication process first then adding

@hoffmann6383 @Cheesehammer11 Shouldn’t we expect 50% of the R&R to be identical to the first R&R? Still leaves the magistrate with the most difficult part to reply to, but just 4 months seems rather long.

@Cheesehammer11 Between today and 2ish months from now would be my guess 😉 We were spoiled on the first R&R. We got it in record time. In Harrington the MTD decision took 8 months. We had a new magistrate and he was probably not as busy which allowed him to get the decision out quickly.

🎭Hedge Funds Unmasked🎭 Hedge funds and any other entities spoofing $NWBO's stock will be identified via discovery after/if the MTD is denied. See the below language from yesterday's status conference in another spoofing case in the Southern District of New York where defendant market makers were forced to disclose their clients' identities. The Defendant Market Makers in $NWBO's spoofing case who may have to disclose their clients' identities: Canaccord Genuity LLC @CG_Driven, Citadel Securities LLC @citsecurities, G1 Execution Services LLC, GTS Securities LLC @gts_capital, Instinet LLC @Instinet , Lime Trading Corp. @LimeTrading_ , and Virtu Americas LLC @VirtuFinancial The Case: Northwest Biotherapeutics, Inc v. Canaccord Genuity LLC, 1:22-cv-10185, (S.D.N.Y.)

@MDendream @Nwbofactcheck EU or FDA is quite similar in MHO but I agree that management should communicate the way forward better. All (incl. funds) still scared about the larger HF can act. I do believe that if this risk dissolves, market capital will be valued against the science

@Nwbofactcheck While news, it isn’t real news. There are only three pieces of news that will move the stock at this point $NWBO Baby bear (UK approval) Big sister bear (EU approval) and Godzilla (FDA approval). The impact is in order from very little to a great big deal

frontiersin.org/journals/immun… Maybe this is why we had a small spike today. DcVax being mentioned in a positive phase ll combo trial is great news. We just need approval and mgmt to hand this off into well equipped BP hands. I’m shocked the pumpers didn’t pump this actual news $NWBO

@justinkeister5 Okay, thanks

@PeptiSense No. Not directly injected. It appears to be loaded exteriorly with neoantigen.

This trial is not #DCVAX per se, but applies similar principals and requires DC isolation and loading. Key difference appears to be target specificity rather than using resected tumor lysate.m for loading. Building from successful trials is common in science. $NWBO

@FlemmingBruce Why not move the the London Stock Exchange or Euronext?

The case is, if those events were to occur, an R/S wouldn't be necessary at all. If we trade at $0.45 it ought to be evident, that there is no more room to spoof the price further down If NWBO choose to R/S FROM such a level, it doesn't take a genius to do some basic math 4/12

$NWBO A case AGAINST reverse split (R/S) Once again we have the "tool" R/S mentioned, as a mean with which we can uplist to Nasdaq and get institutions to buy in. I have earlier pleaded my case against it and will continue to do so. 1/12